KPIs & Operating Metrics(New)

Balance Sheet

Cash Flow Statement

Acquisitions Amortization of Deferred Charges Amortization of Deferred Charges Amortization of Goodwill Amortization of Goodwill Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Preferred Shares Issued Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Short-Term Debt issuances Short-Term Debt repayments

Daily Values

Growth Metrics

Bionano Genomics (BNGO) Long-Term Debt Issuances (2018 - 2023)

Bionano Genomics (BNGO) has disclosed Long-Term Debt Issuances for 4 consecutive years, with $80.0 million as the latest value for Q4 2023.

Quarterly Long-Term Debt Issuances changed N/A to $80.0 million in Q4 2023 from the year-ago period, while the trailing twelve-month figure was $80.0 million through Sep 2025, down 0.94% year-over-year, with the annual reading at $18.0 million for FY2024, 77.5% down from the prior year.
Long-Term Debt Issuances hit $80.0 million in Q4 2023 for Bionano Genomics, up from $761000.0 in the prior quarter.
In the past five years, Long-Term Debt Issuances ranged from a high of $80.0 million in Q4 2023 to a low of -$38000.0 in Q3 2019.
Historically, Long-Term Debt Issuances has averaged $20.0 million across 3 years, with a median of $761000.0 in 2020.
Biggest five-year swings in Long-Term Debt Issuances: tumbled 100.24% in 2019 and later skyrocketed 2300.95% in 2020.
Year by year, Long-Term Debt Issuances stood at -$34576.0 in 2019, then surged by 2300.95% to $761000.0 in 2020, then soared by 10412.48% to $80.0 million in 2023.
Business Quant data shows Long-Term Debt Issuances for BNGO at $80.0 million in Q4 2023, $761000.0 in Q4 2020, and -$34576.0 in Q4 2019.